Amarin delays free speech settlement with FDA

Amarin Corp. plc (NASDAQ:AMRN) requested that a district court again delay further proceedings in its free speech suit against FDA.

The company filed a letter with the U.S. District Court for the Southern District of New York stating the parties "have engaged in and continue to engage in settlement discussions," and requested a stay of proceedings until Feb. 17. Amarin and FDA were due to report back on the negotiations on Thursday (see BioCentury Extra, Oct. 30). ...